MedTrace Logo

Developmental Outcomes

NCT02264808 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2020-01-18

No results posted yet for this study

Summary

Determine whether the concentrations of UCH-L1 and GFAP measured in umbilical cord blood and in blood 0-6 hours postnatal accurately predict the extent of neurodevelopmental deficits and/or death at 18-20 months.

Conditions

  • Hypoxic-Ischemic Encephalopathy

Interventions

OTHER

Developmental Outcomes

A Bayley-III developmental assessment will be performed study subjects at age 18-20 months

Sponsors & Collaborators

Principal Investigators

  • Michael D Weiss, MD · University of Florida

Eligibility

Min Age
18 Months
Max Age
20 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2018-12-03
Completion
2018-12-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02264808 on ClinicalTrials.gov